Jim Murray: Will governments support transparency for clinical trials?

Criticism of EU law is often aimed at an amorphous “Brussels,” but in many cases member states are the problem—as with the proposal to revise the Clinical Trials Directive. The proposal envisages a central EU portal and database of applications, assessments, safety reports, and other information about clinical trials. How comprehensive will that information be, […]

Read More…

Jim Murray: The EMA’s efforts to widen access to clinical trial results

The European Medicines Agency is trying to widen access to clinical trial results for medicines that have been authorised. Its efforts have been blocked, at least temporarily, by a legal challenge in the European Courts from AbbVie, in a case involving the medicine Humira. AbbVie is in effect the former medicines division of Abbot Laboratories. […]

Read More…